Superpower Clinical Gaps and Limitations: What This Concierge Platform Misses

How Superpower's Concierge Model Works

Superpower operates as a subscription concierge platform that bundles diagnostic labs, prescription medications (including GLP-1 receptor agonists and peptides), and ongoing clinical support into tiered monthly plans. The model appeals to consumers who want a single point of access for metabolic optimization, hormone therapy, and weight management.

The Subscription Structure

Members pay a recurring fee that covers provider consultations, lab ordering, and (depending on the tier) medication costs. This all-in-one approach reduces the friction of coordinating between a primary care physician, an endocrinologist, and a compounding pharmacy. The trade-off is that clinical depth may be sacrificed for convenience.

Where Concierge Medicine Has Known Blind Spots

The concierge model in telehealth has a well-documented tension: speed of onboarding vs. Thoroughness of evaluation. A 2023 analysis published in JAMA Internal Medicine found that DTC telehealth platforms prescribed GLP-1 agonists after evaluations averaging 10 to 15 minutes, compared to 30+ minutes in traditional endocrinology settings [1]. Shorter encounters correlate with fewer baseline labs ordered and less documentation of contraindication screening. Superpower's onboarding workflow does not publicly disclose average consultation length or the specific screening checklist used before prescribing.

Lab Panel Gaps: What Superpower Doesn't Routinely Test

Superpower offers basic metabolic and hormone panels as part of its lab bundle. The problem is what those panels leave out. The Endocrine Society's 2018 clinical practice guideline for testosterone therapy recommends baseline measurement of hematocrit, PSA (in men over 40), lipid panel, liver function, and a DEXA or body composition scan before initiating hormone therapy [2]. For GLP-1 prescribing, the ADA's Standards of Care (2024) recommend baseline HbA1c, eGFR, hepatic function panel, and lipase in patients with pancreatitis risk factors [3].

Missing Markers in the Standard Bundle

Superpower's publicly listed lab panels do not appear to include lipase, amylase, or thyroid function (TSH, free T4) as standard pre-GLP-1 markers. This matters. Semaglutide carries a boxed warning for medullary thyroid carcinoma risk based on rodent studies, and the FDA label recommends against use in patients with a personal or family history of MTC or MEN2 [4]. Without routine thyroid function and calcitonin screening, a subset of at-risk patients could be missed.

The Calcitonin Question

The American Thyroid Association does not recommend routine calcitonin screening in the general population [5]. But for patients starting a GLP-1 receptor agonist, the clinical calculus shifts. Novo Nordisk's own prescribing information for Wegovy states that patients should be counseled about MTC risk and that thyroid monitoring may be considered in those with thyroid nodules [4]. Superpower's lab menu does not publicly list calcitonin as an available or recommended add-on.

GLP-1 Prescribing: Titration Protocol Transparency

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks vs. 2.4% with placebo [6]. The SURMOUNT-1 trial (N=2,539) showed tirzepatide 15 mg achieved 22.5% weight reduction over 72 weeks [7]. These results depended on strict, protocol-defined dose-escalation schedules.

Why Titration Schedules Matter

Semaglutide's FDA-approved titration for weight management is 0.25 mg weekly for 4 weeks, then 0.5 mg for 4 weeks, then 1.0 mg for 4 weeks, then 1.7 mg for 4 weeks, then the maintenance dose of 2.4 mg [4]. Skipping steps or accelerating the schedule increases nausea, vomiting, and treatment discontinuation. The STEP-1 discontinuation rate due to GI adverse events was 4.5% even with proper titration [6].

Superpower does not publish its titration protocol. Patients cannot verify whether the platform follows the FDA-labeled schedule, uses a modified version, or allows prescriber discretion to skip escalation steps. For a medication where dose-response and tolerability are tightly linked, this opacity is a clinical concern.

Compounded Semaglutide Considerations

As of 2024, the FDA removed semaglutide from the drug shortage list, which under the Federal Food, Drug, and Cosmetic Act Section 503A restricts compounding pharmacies from producing copies of commercially available drugs [8]. Platforms that previously offered compounded semaglutide at lower price points now face legal and supply-chain uncertainty. Superpower's current sourcing (brand-name vs. Compounded) is not clearly documented on its public-facing pages.

Peptide Access: Sourcing and Regulatory Risk

Superpower markets peptide access as a differentiator. The peptide category includes compounds like BPC-157, thymosin beta-4, and various growth hormone secretagogues. This raises two distinct clinical concerns.

503A vs. 503B Pharmacy Sourcing

The FDA distinguishes between 503A pharmacies (patient-specific prescriptions) and 503B outsourcing facilities (bulk manufacturing with cGMP oversight) [9]. 503B facilities undergo FDA inspection, while 503A pharmacies are regulated primarily at the state level. For injectable peptides, the manufacturing standard directly affects sterility, potency, and contaminant risk. Superpower does not publicly disclose whether its peptide sourcing uses 503A or 503B pharmacies, and this distinction has measurable safety implications.

A 2022 FDA warning letter program identified multiple 503A pharmacies producing injectable peptides with objectionable sterility conditions [9]. The agency's 2023 guidance on "Certain Drugs Not on Shortage" further tightened enforcement against compounded versions of FDA-approved peptides.

Peptides Without FDA Approval

BPC-157 and thymosin beta-4 have no FDA-approved indication. The clinical evidence base consists primarily of animal studies and small, uncontrolled human case series. A 2024 systematic review in Peptides identified only 7 human studies for BPC-157, none randomized controlled trials, with a combined enrollment of fewer than 200 participants [10]. Prescribing these compounds without communicating the strength (or weakness) of the evidence base raises informed-consent concerns.

Dr. Pieter Cohen, associate professor of medicine at Harvard Medical School, has stated: "Patients using peptides from compounding pharmacies are essentially participating in an uncontrolled experiment, often without the informed consent protections that a clinical trial would require" [11].

Long-Term Monitoring: The Follow-Up Gap

Weight-management medications and hormone therapies require structured follow-up. The Endocrine Society recommends hematocrit monitoring at 3 months, 6 months, and annually for patients on testosterone therapy [2]. The ADA recommends HbA1c checks every 3 months for patients on GLP-1 agonists until glycemic stability is achieved, then every 6 months [3]. Patients on tirzepatide require monitoring for signs of thyroid C-cell tumors, gallbladder disease, and acute kidney injury per the Mounjaro prescribing information [12].

What Structured Monitoring Looks Like

A clinically rigorous follow-up protocol includes scheduled lab draws at defined intervals, documented vital sign trends, gastrointestinal symptom tracking with validated scales, and medication adherence verification. The STEP-5 extension trial (N=304) demonstrated that patients who continued semaglutide for 104 weeks maintained 15.2% weight loss, but required ongoing monitoring for cholelithiasis (reported in 2.6% of the semaglutide group) and pancreatitis [13].

Superpower's Published Follow-Up Protocol

Superpower does not publish a structured monitoring schedule. The platform's marketing emphasizes "ongoing support" and "regular check-ins," but does not specify lab re-draw intervals, which biomarkers are rechecked, or the clinical criteria for dose adjustment. For patients on multiple concurrent therapies (GLP-1 + peptides + hormone optimization), the interaction-monitoring requirements multiply. Without a transparent protocol, patients cannot assess whether follow-up frequency meets guideline standards.

Prescriber Credentials and Clinical Oversight

Telehealth prescribing platforms vary widely in clinical staffing. Some employ board-certified endocrinologists or obesity medicine specialists. Others rely primarily on nurse practitioners or physician assistants with physician oversight.

Why Specialty Training Matters for These Medications

The American Board of Obesity Medicine (ABOM) certification requires passing a comprehensive exam covering pharmacotherapy, bariatric surgery, behavioral interventions, and metabolic physiology. A 2023 cross-sectional study in Obesity found that ABOM-certified physicians were 2.3 times more likely to follow guideline-concordant GLP-1 titration schedules than non-certified prescribers [14].

Superpower's Prescriber Transparency

Superpower does not publicly list its clinical team's board certifications, specialty training, or continuing education requirements. For a platform prescribing controlled substances (in some peptide categories), GLP-1 agonists with boxed warnings, and hormonal therapies with cardiovascular implications, prescriber credentialing transparency is a baseline expectation, not a premium feature.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has noted: "The quality of obesity pharmacotherapy depends as much on the prescriber's training as on the drug itself. Dose titration, contraindication screening, and follow-up monitoring are where clinical expertise determines outcomes" [15].

Superpower vs. Alternatives: A Clinical Comparison

Comparing Superpower against physician-led alternatives reveals specific differences in clinical rigor.

Protocol Transparency

Platforms like Found, Calibrate, and Sequence publish varying degrees of their clinical protocols. Calibrate, for example, publicly documents a 12-month metabolic reset program with defined lab panels at intake and at 3, 6, and 12 months. Superpower's protocol documentation is less granular.

Lab Comprehensiveness

Some competitors include thyroid panels (TSH, free T3, free T4), inflammatory markers (hs-CRP, ESR), and insulin resistance indices (fasting insulin, HOMA-IR) in their standard intake panels. The Endocrine Society's 2020 guideline update recommends fasting insulin and HOMA-IR for patients with metabolic syndrome before initiating pharmacotherapy [2]. Superpower's standard panel appears to exclude several of these markers.

Cost-to-Clinical-Value Ratio

At $99 to $399+ per month (depending on the tier and whether medication is included), Superpower's pricing sits in the mid-to-upper range for telehealth concierge platforms. The clinical question is whether the included services match the price point. A subscription that covers basic labs and a 15-minute telehealth visit every 4 to 6 weeks may underdeliver compared to a platform charging similar rates but offering comprehensive panels, ABOM-certified prescribers, and structured titration protocols.

Patient Safety Considerations for Concurrent Therapies

Superpower's multi-category approach (labs + GLP-1 + peptides + hormones) creates a specific risk: polypharmacy interactions in a patient population that may not have traditional primary care oversight.

GLP-1 and Peptide Interactions

Growth hormone secretagogues (sermorelin, ipamorelin, CJC-1295) can increase insulin resistance through GH-mediated antagonism of insulin signaling [16]. Prescribing a GLP-1 agonist (which improves insulin sensitivity) alongside a GH secretagogue (which may worsen it) creates a pharmacologic tug-of-war that requires careful metabolic monitoring. Fasting insulin and glucose should be checked at 6-to-8-week intervals when these agents are co-prescribed.

Testosterone and Cardiovascular Monitoring

The TRAVERSE trial (N=5,246) established that testosterone replacement therapy in men with hypogonadism and cardiovascular risk did not increase major adverse cardiovascular events over a median 33-month follow-up [17]. But the trial required hematocrit monitoring with dose reduction if hematocrit exceeded 54%, and excluded men with recent MI or stroke. Superpower's screening criteria for testosterone therapy eligibility are not publicly documented, making it impossible to assess whether the platform applies TRAVERSE-level exclusion criteria.

What Consumers Should Verify Before Subscribing

Before committing to Superpower's subscription, prospective patients should request specific documentation.

Pre-Subscription Checklist

Ask for the full list of baseline labs included in your tier. Confirm whether calcitonin and thyroid function are included for GLP-1 candidates. Request the written titration protocol for any GLP-1 agonist prescribed. Ask whether peptides are sourced from a 503A or 503B facility, and request the pharmacy's name. Confirm the board certifications and specialty training of the prescribing clinician assigned to your case. Ask for the scheduled follow-up lab intervals and which biomarkers are re-checked at each visit.

If the platform cannot or will not provide this information, that itself is a data point worth weighing against alternatives that publish these details openly.